Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SOBI002 Following Subcutaneous and Intravenous Administration. A Double-blind, Placebo-controlled, Randomized Within Dose Cohort, Single and Repeated Dose-escalation Study in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 30 Jul 2015
At a glance
- Drugs SOBI 002 (Primary) ; SOBI 002 (Primary)
- Indications Autoimmune disorders; Inflammation
- Focus Adverse reactions
- Sponsors Swedish Orphan Biovitrum
- 27 Jul 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 09 Nov 2014 Status changed from recruiting to suspended, as reported by ClinicalTrials.gov.
- 24 Mar 2014 New trial record